You are here

Home » Content

Radyoterapi Uygulanan Jinekolojik Tümör Tanılı Olgularda Tedavi Sonuçları ve Prognostik Faktörler

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Journal Name:

  • Akdeniz Tıp Dergisi

Publication Year:

  • 2015
DOI: 
10.17954/amj.2015.27

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: To evaluate the patients with gynecologic tumors undergoing radiotherapy. Material and Methods: Seventy-eight patients with a diagnosis of gynecological malignancy who received curative radiotherapy (RT) between June 2010-January 2013 were retrospectively evaluated. Results: We treated 33, 44 and 1 patient for cervical cancer, endometrial cancer and endocervical canal tumor respectively. The median age was 56 years (34–83). The mean follow-up period was 23.9±1.4 months. At the time of diagnosis, 18 (23.1%) patients were premenopausal whereas 60 (74.9%) patients were postmenopausal. Thirty-one endometrial cancer patients received adjuvant RT while 9 received adjuvant chemotherapy and RT. Five of the patients with a diagnosis of recurrent endometrial cancer received RT after salvage surgery. Sixteen patients with locally advanced cervical cancer were treated with defi nitive chemoradiotherapy. Ten patients (30.3%) who were operated on for cervical cancer were administered adjuvant RT whereas 6 patients (18.2%) received adjuvant chemoradiotherapy. The patient with endocervical canal tumor received adjuvant chemoradiotherapy. The median overall survivals were 26.3 and 21.1 months for patients with endometrial and cervical cancer respectively. Cox-regression analyses revealed that there was a relationship between the overall survival and local recurrence (p=0.046), tumor diameter (p= 0.030) and stage (p= 0.036); on the other hand there was no relationship between the overall survival and lymphovascular invasion (p=0.711) and myometrial invasion (p=0.684). Conclusion: Survival in endometrial cancer is associated with local recurrence, maximal tumor diameter and stage. For cervical cancer, there is a close association with lymph node involvement and disease-free survival.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Radyoterapi tedavisi alan jinekolojik tümörlü hastaların değerlendirilmesi. Gereç ve Yöntemler: Haziran 2010-Ocak 2013 tarihleri arasında küratif radyoterapi (RT) uygulanan 78 jinekolojik tümörlü hasta retrospektif olarak değerlendirildi. Bulgular: Olguların 33’ü serviks kanseri, 44’ü endometriyum kanseri ve 1’i endoservikal kanal tümörü nedeni ile tedavi edildi. Medyan yaşı 56 idi (aralık: 34–83 ). Ortalama izlem süresi 23,9±1,4 ay idi. Tanı anında 18 hasta (%23,1) premenopozal, 60 hasta (%74,9) postmenopozaldi. Endometriyum kanseri nedeni ile opere edilen olguların 31’i adjuvan RT alırken; 9 olgu postoperatif KT ve RT aldı. Endometriyum kanseri tanısı olan 5 hasta nüks nedeni ile kurtarma cerrahisi ardından RT aldı. Serviks kanseri nedeni ile RT uygulanan hastaların 16’sına lokal ileri evre serviks kanseri nedeni ile defi nitif kemoradyoterapi uygulandı. On (%30,3) serviks kanseri tanılı olgu ise adjuvan RT; 6 hasta (%18,2) adjuvan kemoradyoterapi (KRT), 1 olgu ise (%3) kurtarma amaçlı RT aldı. Endoservikal kanal tümörü tanısı olan hastaya adjuvan KRT uygulandı. Endometriyum kanseri nedeni ile RT uygulanan hastalarda medyan sağkalım 26,3 ay, serviks kanseri nedeni ile RT uygulanan hastalarda ise 21,1 ay olarak bulundu. Endometriyum kanseri tanısı ile tedavi edilen hastalarda cox-regresyon analizinde lokal nüks (p=0,046) , tümör çapı (p= 0,030) ve evrenin (p= 0,036) sağkalım ile ilişkisi gösterilirken; lenfovasküler alan invazyonu (p=0,711), myometriyal invazyonun (p=0,684) sağkalım ile ilişkisi gösterilememiştir. Serviks kanseri nedeni ile tedavi edilen hastalarda ise lenf nodu pozitifl iği ile progresyonsuz hastalık arasında ilişki gösterilmiştir (p=0,043). Sonuç: Endometriyum kanserinde lokal nüks , tümör çapı ve evre sağkalım ile ilişkilidir. Serviks kanserinde ise lenf nodu pozitifl iği ile progresyonsuz hastalık arasında ilişki mevcuttur.
FULL TEXT (PDF): 
PDF icon arastirmax-radyoterapi-uygulanan-jinekolojik-tumor-tanili-olgularda-tedavi-sonuclari-prognostik-faktorler.pdf
  • 3
142
149
  • Turkish

REFERENCES

References: 

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J,
Jemal A. Global cancer statistics, 2012. CA Cancer J Clin
2015;65(2):87-108.
2. Anton C, Fávero GM, Köhler C, Carvalho FM, Baracat
EC, Carvalho JP. Surgical treatment of endometrial
cancer in developing countries: Reasons to consider
systematic two-step surgical treatment. Clinics (Sao Paulo)
2015;70(7):470-4.
3. Kanserle Savaş Dairesi Başkanlığı verileri. www.kanser.
gov.tr
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.
Cancer statistics, 2007. Cancer J Clin 2007; 57:43-66.
5. Alvarez Secord A, Havrilesky LJ, Bae-Jump V. The role of
multi-modality adjuvant chemotherapy and radiation in
women with advanced stage endometrial cancer. Gynecol
Oncol 2007;107: 285-91.
6. Dogan NU, Yavas G, Yavas C, Ata O, Yılmaz SA, Celik
C. Comparison of “sandwich chemo-radiotherapy”
and six cycles of chemotherapy followed by adjuvant
radiotherapy in patients with stage IIIC endometrial
cancer: A single center experience. Arch Gynecol Obstet
2013;288(4):845-5.
7. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos
NM, Bloss JD. A phase III trial of surgery with or
without adjunctive external pelvic radiation therapy
in intermediate risk endometrial adenocarcinoma; A
gynecologic oncology group study. Gynecol Oncol
2004;92:744-51.
8. Creutzberg CL, van Putten WL, Koper PC, Lybeert
ML, Jobsen JJ, Warlam-Rodenhuis CC. Surgery and
postoperative radiotherapy versus surgery alone for
patients with stage-I endometrial carcinoma: Multicentre
randomized trial. PORTEC Study Group. Post operative
radiation therapy in endometrial carcinoma. Lancet
2000;55:1404-11.
9. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with
concurrent chemotherapy compared with pelvic and
para-aortic radiation for high-risk cervical cancer. N Eng
J Med 1999;340:1137–43.
10. Whitney CW, Sause W, Bundy BN et al. Randomized
comparison of fl uorouracil plus cisplatin versus
hydroxyurea as an adjunct to radiation therapy in stage
IIB-IVA carcinoma of the cervix with negative paraaortic
lymph nodes: A Gynecologic Oncology Group
and Southwest Oncology Group study. J Clin Oncol
1999;17:1339–48. Eifel PJ, Moughan J, Owen J et
al. Patterns of radiotherapy practice for patients with
carcinoma of the uterine cervix: Patterns of Care Study.
Int J Radiat Oncol Biol Phys 1999;43:351-8.
11. Rose PG, Bundy BN, Watkins EB. Concurrent cisplatinbased
chemotherapy and radiotherapy for locally
advanced cervical cancer. N Engl J Med 1999; 340:1144–
53.
12. Nag S, Erickson B, Thomadsen B, Orton C, Demanes
JD, Petereit D. The American Brachytherapy Society
recommendations for high-dose- rate brachytherapy for
carcinoma of the cervix. Int J Radiat Oncol Biol Phys
2000;48:201–11.
13. http://www.rtog.org/CoreLab/ContouringAtlases/
GYN.aspx
14. Small W Jr, Mell LK, Anderson P, Creutzberg C, De
LosSantos J, Gaffney D. Consensus guide lines for
delineation of clinic altar get volume for intensitymodulated
pelvic radiotherapy in postoperative treatment
of endometrial and cervical cancer. Int J Radiat Oncol
Biol Phys 2008;71(2):428-34.
15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the
Radiation Oncology Group (RTOG) and the European
Organization for Research and Treatment of Cancer
(EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341-
46.
16. Grigsby WP, Perez CA, Kuten A. Clinical stage I
endometrial cancer: Results of adjuvant irradiation
and patterns of failure. Int J Radiat Oncol Biol Phys
1992;21:379-85.
17. Grigsby WP, Perez CA, Kuten A. Clinical stage I
endometrial cancer: Prognostic factors for lobal control
and distant metastases and implications of the new FIGO
surgical staging system. Int J Radiat Oncol Biol Phys
1991;22:905-11.
18. Glassburn JR, Brady LW, Grigsby PW. Endometrium,
In: Perez CA, Brady LW, eds. Principles and Practice of
Radiation Oncology. 3rd ed. Philadelphia:Lippincott-
Raven Publishers, 1998,1835-52.
19. Creasman WT, Morrow P, Bundy BN. Surgical pathologic
spread patterns of endometrial cancer: A Gynecologic
Oncology Group Study. Cancer 1987;60:2035-41.
149
Radyoterapi Uygulanan Jinekolojik Tümör Tanılı Olgularda Tedavi Sonuçları ve Prognostik Faktörler
Akd Tıp D / Akd Med J / 2015; 3: 142-149
20. Landoni F. Maneo A, Colombo A. Randomised study
of radical surgery versus radiotherapy for stage Ib-lIa
cervical cancer. Lancet 1997;350:535-40.
21. Moore DH, Stehman FB. What is the appropriate
management of early stage cervical cancer (International
Federation of Gynecology and Obstetrics stages I and
IIA surgical assessment of lymph nodes, and role of
therapeutic resection of lymph nodes involved with
cancer? J Natl Cancer Inst Monogr 1996;(21):43-6.
22. Benedetli-Panici P, Maneschi F, D’Andrea G. Early
cervical carcinoma: The natural history of lymph
node involvement redefi ned on the basis of thorough
parametrectomy and giant section study. Cancer
2000;88:2267-74.
23. Burghardt E, Baltzer J, Tulusan AH. Results of surgical
treatment of 1028 cervical cancers studied with volumetry.
Cancer 1992;70:648-55.
24. Covens A, Rosen B, Murphy J. How important is removal
of the parametrium at surgery for carcinoma of the
cervix? Gynecol Oncol 2002;84: 145-9.
25. Boyce J, Fichter RG, Nicastri AD. Prognostic factors in
stage I carcinoma of the cervix. Gynecol Oncol 1981;
12:154-65.
26. Sedlis A. Bundy BN, Rotman MZ. A randomized trial
of pelvic radiation therapy versus no further therapy in
selected patients with stage IB carcinoma of the cervix
after radical hysterectomy and pelvic lymphadenectomy:
A Gynecologic Oncology Group Study. Gynecol Oncol
1999:73:177-83.
27. Alvarez RD, Potter ME. Soong SJ. Rationale for using
pathologic tumor dimensions and nodal status to
subclassify surgically treated stage I.E cervical cancer
patients. Gynecol Oncol 1991;43:108-12.
28. Okada M, Kigawa J, Minagawa Y. Indication and effi cacy
of radiation therapy following radical surgery in patients
with stage 1.8 to lIB cervical cancer. Gynecol Oncol 1998;
70( I):61-64.
29. Wang X, Shen Y, Zhao Y, Li Z, Gou H. Adjuvant intensitymodulated
radiotherapy (IMRT) with concurrent
paclitaxel and cisplatin in cervical cancer patients with
high risk factors: A phase II trial. Eur J Surg Oncol
2015;41(8):1082-8.
30. Jelavić TB, Miše BP, Strikic A, Ban M, Vrdoljak E. Adjuvant
chemotherapy in locally advanced cervical cancer after
treatment with concomitant chemoradiotherapy - room
for improvement? Anticancer Res 2015 Jul;35(7):4161-5.

Thank you for copying data from http://www.arastirmax.com